Rational design of potent human transthyretin amyloid disease inhibitors (original) (raw)

References

  1. Benson, M. D., Wallace, M. R. “Amyloidosis” In The Metabolic Basis of Inherited Disease (Scrirer, C. R., Beaudet, A. Z., Sly, W. S., Velk, D. eds, New York: McGraw Hill. 2439–2460, 1989).
    Google Scholar
  2. Colon, W. & Kelly, J.W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31, 8654–8660 (1992).
    Article CAS Google Scholar
  3. Kelly, J.W. Alternative conformations of amyloidogenic proteins govern their behavior. Curr. Opin. Struct. Biol. 6, 11–17 (1996).
    Article CAS Google Scholar
  4. Lai, Z., Colon, W. & Kelly, J.W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate which can self-assemble into amyloid. Biochemistry 35, 6470–6482 (1996).
    Article CAS Google Scholar
  5. Kelly, J. W. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol. 8, 101–106 (1998).
    Article CAS Google Scholar
  6. McCutchen, S.L., Lai, Z., Miroy, G.J., Kelly, J.W. & Colon, W. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 34, 13527–36 (1995).
    Article CAS Google Scholar
  7. Jacobson, D.R. & Buxbaum, J.N. Genetic aspects of amyloidosis. Adv. Human Genetics 20, 69–123 (1991).
    Article CAS Google Scholar
  8. Sipe, J.D. Amyloidosis. Crit. Rev. Clin. Lab. Sci. 31, 325–354 (1994).
    Article CAS Google Scholar
  9. Benson, M.D., Uemichi, T. Transthyretin amyloidosis. Amyloid Int. J. Exp. Clin. Invest. 3, 44–56 (1996).
    CAS Google Scholar
  10. Pomerance A. Age-related cardiovascular changes and mechanically induced endocardial pathology. In: Silver MD, ed. Cardiovascular pathology (ed. Silver M.D. 2nd ed. New York: Churchill Livingstone. 155–162, 1991).
    Google Scholar
  11. Hodkinson, H.M., Pomerance, A. The clinical significance of senile cardiac amyloidosis: a prospective clinico-pathological study. Q. J. Med. 46, 381–387 (1977).
    CAS PubMed Google Scholar
  12. Jacobson, D.R. et al. Variant-sequence transthyretin (isoleucin 122) in late-onset cardiac amyloidosis in black americans. N. Engl. J. Med. 336, 466–473 (1997).
    Article CAS Google Scholar
  13. Monaco, H.L., Rizzi, M. & Coda, A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein Science 268, 1039–1041 (1995).
    Article CAS Google Scholar
  14. Nilsson, S. F., Rack, L., Peterson, P. Studies of thyroid hormone binding proteins. J. Biol. Chem. 250, 8554–8563 (1975).
    CAS PubMed Google Scholar
  15. Blake, C.C., Geisow, M.J., Oatley, S.J., Rerat B. & Rerat, C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å. J. Mol. Biol. 121, 339–356 (1978).
    Article CAS Google Scholar
  16. Blake, C.C.F, Geisow, M.J., Swan, I.D., Rerat, C. & Rerat, B. Structure of human plasma prealbumin at 2.5 Å resolution. A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. J. Mol. Biol. 88, 1–12 (1974).
    Article CAS Google Scholar
  17. Miroy, G.J. et al. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl. Acad. Sci. USA 93, 15051–15056 (1996).
    Article CAS Google Scholar
  18. Wojtczak, A., Cody, V., Luft J.R. & Pangborn W. Structures of human transthyretin complexed with thyroxine at 2.0 Å Resolution and 3′-5′-Dinitro-N-acetyl-L-thyroxine at 2.2 Å Resolution. Acta Crystallogr. D 52, 758–765 (1996).
    Article CAS Google Scholar
  19. Peterson, S.A. et al. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc. Natl. Acad. Sci. USA 95, 12956–12960 (1998).
    Article CAS Google Scholar
  20. Coelho, T. Familial amyloid polyneuropathy: new developments in genetics and treatment. Curr. Opin. Neurol. 9, 355–359 (1996).
    Article CAS Google Scholar
  21. Munro, S.L. et al. Drug Competition for thyroxine binding to transthyretin (prealbumin): comparison with effects on thyroxine-binding globulin. J. Clin. Endorinol. Metab. 68, 1141–7 (1989).
    Article CAS Google Scholar
  22. Baures, P.W., Peterson, S.A., Kelly, J.W. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg. Med. Chem. 6, 1389–1401 (1998).
    Article CAS Google Scholar
  23. Baures, P.W., Oza, V.B., Peterson, S.A. & Kelly, J.W. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorg. Med. Chem. 7, 1339–1347 (1999).
    Article CAS Google Scholar
  24. Demrow, H.S, Slane, P.R., Folts, J.D. Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Circulation 91, 1182–88 (1995)
    Article CAS Google Scholar
  25. Bertelli A.A., et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int. J. Tissue React. 17, 1–3 (1995).
    CAS PubMed Google Scholar
  26. MacCarrone M., Lorenzon T., Guerrieri P. & Agro A.F., Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur. J. Biochem. 265, 27–34 (1999).
    Article CAS Google Scholar
  27. Cryer, B. & Feldman, M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J. Med. 104, 413–421 (1998).
    Article CAS Google Scholar
  28. Kurumbail R.G. et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384, 644–648 (1996).
    Article CAS Google Scholar
  29. Oza, V.B., Petrassi, H.M., Purkey, H.E. & Kelly, J.W. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. Bioorg. Med. Chem. Lett 9, 1–6 (1999).
    Article CAS Google Scholar
  30. Horodniak, J.W. et al. Inhibition of prostaglandin synthetase and carrageenan-induced edema by analogs of flufenamic acid. Drugs Exptl. Clin. Res. 2, 35–45 (1977).
    CAS Google Scholar
  31. Petrassi, H. M., Klabunde, T., Sacchettini, J., Kelly, J. W. Structure-based design of N-phenyl phenoxazine transthyretin amyloid fibril inhibitors. J. Am. Chem. Soc. 122, in the press (2000).
  32. Crook P.R., Willis, J.V., Kendall, M.J., Jack, D.B. & Fowler, P.D. The pharmacokinetics of diclofenac sodium in patients with active rheumatoid disease. Eur. J. Clin. Pharmacol. 21, 331–334 (1982).
    Article CAS Google Scholar
  33. Diaz, H., Espina, J. R., Kelly, J. W. A dibenzofuran-based amino acid designed to nucleate antiparrallel β-sheet structure: evidence for intramolecular hydrogen-bond formation. J. Am. Chem. Soc. Am 114, 8316–8318 (1992).
    Article CAS Google Scholar
  34. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data in oscillation mode. Methods Enz. 276, 307–326 (1997).
    Article CAS Google Scholar
  35. Brünger, A.T. Crystallography & NMR System. Acta Crystallogr. D 54, 905–921 (1998).
    Article Google Scholar
  36. Jones, T.A., Zou, J.-Y., Cowan, S.W. & Kjeldgaard, M. Improved method for building protein models in electron-density maps and the location of errors in these models. Acta Crystallogr. A 47, 110–119 (1991).
    Article Google Scholar
  37. Evans, S. V. SETOR: Hardware lighted three-dimensional solid model representations of macromolecules. J. Mol. Graphics 11, 134–138 (1993).
    Article CAS Google Scholar

Download references